Centessa Pharmaceuticals (CNTA) shares soared nearly 44% on Tuesday following Eli Lilly’s (LLY) announcement of a definitive agreement to acquire the company for up to $7.8 billion. The acquisition price of $38 per share represents a nearly 38% premium over Centessa’s previous closing price. Additionally, Centessa shareholders will receive a contingent value right that could add up to $9 per share based on the success of its investigational drugs.
This acquisition is significant for the financial markets as it highlights Lilly’s strategic move to bolster its pipeline with Centessa’s innovative orexin receptor 2 (OX2R) agonists, aimed at treating severe sleep disorders. With a potential market size of $20 billion, these therapies could become major revenue drivers, especially as Lilly leverages profits from its successful GLP-1 drugs to diversify its offerings.
For market professionals, this deal underscores the ongoing trend of consolidation in the biotech sector, as established firms seek to enhance their portfolios with promising drug candidates to secure future growth.
Source: fool.com